Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
Overview
- Phase
- Phase 4
- Intervention
- amoxicillin
- Conditions
- Antimicrobial Susceptibility Testing
- Sponsor
- Yanqing Li
- Enrollment
- 120
- Primary Endpoint
- Eradication rate of AST guided triple therapy
- Last Updated
- 9 years ago
Overview
Brief Summary
Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.
Investigators
Yanqing Li
Vice president of Qilu Hospital
Shandong University
Eligibility Criteria
Inclusion Criteria
- •Consecutive patients who are 18-70 years old with persistent H. pylori infection after first or second line treatment attempts.
Exclusion Criteria
- •Enable to undergo upper endoscopy;
- •Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;
- •Known or suspected allergy to study medications;
- •Taking bismuth and antibiotics in the previous four weeks, or taking proton pump inhibitor and H2-receptor blockers in the previous two weeks;
- •Currently pregnant or lactating
- •Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.
Arms & Interventions
clarithromycin susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI).
Intervention: amoxicillin
clarithromycin susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI).
Intervention: clarithromycin
clarithromycin susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI).
Intervention: Ilaprazole
metronidazole susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
Intervention: amoxicillin
metronidazole susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
Intervention: tinidazole
metronidazole susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
Intervention: Ilaprazole
levofloxacin susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
Intervention: amoxicillin
levofloxacin susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
Intervention: levofloxacin
levofloxacin susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
Intervention: Ilaprazole
furazolidone susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
Intervention: amoxicillin
furazolidone susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
Intervention: furazolidone
furazolidone susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
Intervention: Ilaprazole
tetracycline susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
Intervention: amoxicillin
tetracycline susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
Intervention: tetracycline
tetracycline susceptible
Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
Intervention: Ilaprazole
Outcomes
Primary Outcomes
Eradication rate of AST guided triple therapy
Time Frame: 3 months
Secondary Outcomes
- the rate of good compliance (take pills more than 90%)(3 months)
- the rate of adverse events happening(3 months)
- the rate of improving dyspepsia symptoms after H. pylori eradication(3 months)